Smartlab Europe

RaySearch unveils new version of RayStation treatment planning system

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.
- Advertisement -

RaySearch Laboratories has launched a new version of its RayStation treatment planning system for clinical use in the European Union, the US, Japan and Australia.

The new RayStation 3.5 version includes a wide range of new features and improvements, including radiation therapy with electrons and protons, along with a Proton Beam Design module.

Proton Beam Design module contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams.

The proton planning functionality in RayStation, will be followed by many other features, such as Pencil Beam Scanning techniques and Monte Carlo dose calculations.

The new version also comprises Electron Beam Design, which includes a Monte Carlo dose engine for electron radiation therapy and tools for manual editing of beams similar to its earlier 3D-CRT module.

RayStation 3.5 also has new features to the existing IMRT and VMAT modules, which offer the possibility to perform all IMRT and VMAT delivery modes available with all relevant machines from the hardware suppliers.

The new version also offers a broad range of new tools, which includes introduction of Plan Generation Protocols, that help for a better planning workflow and automating tedious treatment planning tasks.

RaySearch CEO Johan Löf said the firms new software version offers support for all treatment modalities and support all IMRT and VMAT delivery modes with all relevant treatment machines.

“RayStation® had already set the standard in terms of usability and with the introduction of Plan Generation Protocols and Fallback Planning we further extend our lead. RayStation® takes a big leap forward to eliminate all unnecessary tedious manual steps and lets the user focus all energy on reviewing, improving and adapting the treatment plans, which are the tasks where the clinical experience matters the most,” Löf added.

 

Latest stories

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Advancing Quality 4.0 Through Centralized Drug Knowledge 

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »